Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Tissue-Engineering Market in 5 Asian Areas to Approach 700 Billion Yen in 2030: Fuji Keizai
July 30, 2021
- Pfizer Japan Recalling Some Champix Products after Detecting Carcinogen
July 29, 2021
- Toray, Veritas Tie Up to Discover Small Molecule Drugs Targeting mRNA
July 29, 2021
- Shionogi in Talks with Vietnam Govt on Vaccine Tech Transfer
July 29, 2021
- European Panel Rejects Kyowa Kirin’s Parkinson’s Med
July 29, 2021
- Kyowa Kirin Files Bardoxolone Methyl in Japan for Alport Syndrome
July 29, 2021
- Ayumi Adjusts Shipments for RA Med Rimatil Impacted by Peers' Unstable Supplies
July 29, 2021
- Towa’s Shipment Curbs Now Affect 319 Products, Active Vitamin Analogs Too
July 29, 2021
- Keytruda Keeps Top Drug Crown in FY2020 despite Double-Digit Dip: Tally
July 28, 2021
- MSD Urges Expansion of Exclusion Criteria for Spillover Rules as Repeated Cuts Hit Keytruda
July 28, 2021
- Meiji to Sell JV Stake to Dong-A, but Will Continue Biosimilar Collaboration
July 28, 2021
- Takeda, PeptiDream Expand Collaboration into Neurodegenerative Disease Area
July 28, 2021
- Daiichi Sankyo Espha, Meiji Pharma Launch Cymbalta Generics
July 28, 2021
- AnGes Adds High-Dose Trial to COVID-19 Vaccine Program
July 27, 2021
- Chugai’s H1 Sales Rise on Growth of Tecentriq, Kadcyla
July 27, 2021
- Shionogi’s Oral COVID-19 Drug Enters PI in Japan
July 27, 2021
- Moderna Vaccine’s Minimum Age Lowered to 12 in Japan
July 27, 2021
- Lenvima/Keytruda Gets Full US Approval for Endometrial Carcinoma
July 27, 2021
- Meiji Pharma Licenses Stelara Biosimilar to India’s Intas
July 26, 2021
- Rohto Begins Japan PIII for Topical Ganciclovir in CMV Corneal Endotheliitis
July 21, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…